Dong-A ST said Tuesday that it recorded sales of 140.8 billion won ($123.5 million) in the third quarter of this year, a 2.1 percent drop from the previous quarter.
“The ETC (Ethical The Counter) drug division's sales fell due to a decrease in business days during the Chuseok holiday, but turnover growth thanks to flagship products such as Suganon and Jublia was encouraging,” a company official said.
The overseas sale also declined over the cited period, as the company had a delay in the bidding for Growtropin-II in the first half of last year, which concentrated 2017 sales in the second half. That made the third quarter sales appear relatively sluggish, the official said. However, sales of Bacchus increased sharply compared to 2017, he added.
Dong-A ST also registered an operating profit of 8.2 billion won, losing more than 48.6 percent from the previous quarter, and posted a net profit of 6.1 billion won, which plunged 45.4 percent.
Despite the drop in profit, the company managed to increase funds for its research and development (R&D) to 17.1 billion won, a 7.1 percent increase from 2017.